OCUL Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 17.96%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 65.98%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 1.91%. Given that Ocular Therapeutix, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Ocular Therapeutix, Inc. is more attractive than Bristol Myers Squibb Co..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.73% to investors and pays a quarterly dividend of $0.62 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 45.28x versus 2.22x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 81.15%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 65.98%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $217.70 which suggests that it could fall by -8.85%. Given that Ocular Therapeutix, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Krystal Biotech, Inc..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 36.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 45.28x versus 19.56x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of -255.85%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 65.98%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -69.64%. Given that Ocular Therapeutix, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 45.28x versus 5.44x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 34.76%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 65.98%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $489.48 which suggests that it could grow by 8.28%. Given that Ocular Therapeutix, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 45.28x versus 9.98x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.